Meanwhile, GSK consumer spinoff Haleon increased its payout by 150 per cent and Park Plaza, and art'otel owner PPHE Hotels ...

Puneet Gulati has been appointed as the Chief Marketing Officer (CMO) at Sleepwell, a role he began in September 2024, as ...

Pascal Soriot is stuck in a Chinese limbo. In recent months, the CEO of $205 billion drug giant AstraZeneca has seen his ...

With that in mind, GSK is partnering with developer Reef and investor UBS Asset Management to build a 1.4M SF, £900M life ...

The data include an interim look at the dose-escalation portion of a phase 2 trial assessing the adenosine A2A receptor ...

Updated results from the DREAMM-7 trial support the use of belantamab mafodotin plus bortezomib and dexamethasone “as a potential new standard of care,” according to Vania Hungria, MD, PhD.

November 2024 has seen a variety of biotech deals take place to advance therapies across different stages in development.

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...

Background With higher valency pneumococcal vaccines on the horizon and new adult immunisation strategies under discussion, ...

Relation Therapeutics Ltd. has delivered the first commercial validation of its combined wet lab/in silico platform for ...

The multi-programme partnership will also see Relation applying its platform to a range of fibrotic conditions as well as ...